Page 166 - 2021_12-Haematologica-web

M.N. Zeissig et al.
study suggests that CCR1 is a potential attractive therapeu- tic target for MM. Future preclinical studies are warranted to investigate whether therapeutic inhibition of CCR1 has efficacy as a maintenance therapy, extending post-therapy remission and preventing overt relapse.
Disclosure
No conflicst of interest to disclose.
Contributions
MNZ performed experiments and wrote the manuscript; KV, DRH, KMM and VP assisted with experiments; KV, ACWZ, DRH and VP reviewed the manuscript; KV, ACWZ, PIC and LBT designed the study; KV, ACWZ and DRH supervised the study. All authors read and approved the final manuscript.
Acknowledgments
The authors thank ChemoCentryx for generously providing the CCR1 antagonist CCX9588 for these studies. We are grateful to Vicki Wilczek and Elyse Bell for their assistance with the animal studies.
Funding
This research was supported by grant 2002138 awarded through the 2020 Priority-driven Collaborative Cancer Research Scheme (PdCCRS), co-funded by Cancer Australia and Cure Cancer, and grant 1163245 awarded through the 2018 PdCCRS, co-funded by Cancer Australia, Cure Cancer, and Leukaemia Foundation of Australia, awarded to KV. The work was partially supported by a Hans-Jürgen and Marianne Ohff Research Grant from the University of Adelaide, awarded to MZ. MZ was supported by the Florey Medical Research Foundation Doctor Chun Chung Wong and Madam So Sau Lam Memorial Postgraduate Cancer Research Top-Up Scholarship and a Short-Term Research Grant from the German Academic Exchange Service (DAAD). VP was sup- ported by a National Health & Medical Research Council Early Career Fellowship. KV and KMM were supported by Early Career Cancer Research Fellowships from the Cancer Council SA Beat Cancer Project on behalf of its donors and the State Government of South Australia through the Department of Health.
References
1. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15 (12):e538-548.
2. Ghobrial IM. Myeloma as a model for the process of metastasis: implications for ther- apy. Blood. 2012;120(1):20-30.
3. Gonsalves WI, Rajkumar SV, Gupta V, et al. Quantification of clonal circulating plasma cells in newly diagnosed multiple myelo- ma: implications for redefining high-risk myeloma. Leukemia. 2014;28(10):2060- 2065.
4. Chakraborty R, Muchtar E, Kumar SK, et al. Risk stratification in myeloma by detec- tion of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer J. 2016;6(12):e512.
5. Chakraborty R, Muchtar E, Kumar SK, et al. Serial measurements of circulating plas- ma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergo- ing upfront autologous transplantation. Haematologica. 2017;102(8):1439-1445.
6. Peceliunas V, Janiulioniene A, Matuzeviciene R, Zvirblis T, Griskevicius L. Circulating plasma cells predict the out- come of relapsed or refractory multiple myeloma. Leuk Lymphoma. 2012;53(4): 641-647.
7. Dingli D, Nowakowski GS, Dispenzieri A, et al. Flow cytometric detection of circulat- ing myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood. 2006;107(8):3384-3388.
8. Nowakowski GS, Witzig TE, Dingli D, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multi- ple myeloma. Blood. 2005;106(7):2276- 2279.
9. Witzig TE, Gertz MA, Lust JA, Kyle RA, O'Fallon WM, Greipp PR. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myelo- ma. Blood. 1996;88(5):1780-1787.
10. Bianchi G, Kyle RA, Larson DR, et al. High levels of peripheral blood circulating plas- ma cells as a specific risk factor for progres- sion of smoldering multiple myeloma. Leukemia. 2013;27(3):680-685.
11. Kumar S, Rajkumar SV, Kyle RA, et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undeter- mined significance. J Clin Oncol. 2005;23(24):5668-5674.
12. Gonsalves WI, Rajkumar SV, Dispenzieri A, et al. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smolder- ing multiple myeloma at high risk of pro- gression. Leukemia. 2017;31(1):130-135.
13. Sanz-Rodríguez F, Ruiz-Velasco N, Pascual- Salcedo D, Teixidó J. Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1. Br J Haematol. 1999;107(4):825-834.
14. Nie Y, Waite J, Brewer F, Sunshine MJ, Littman DR, Zou YR. The role of CXCR4 in maintaining peripheral B cell compart- ments and humoral immunity. J Exp Med. 2004;200(9):1145-1156.
15.Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009;113(18):4341-4351.
16.Azab AK, Hu J, Quang P, et al. Hypoxia promotes dissemination of multiple myelo- ma through acquisition of epithelial to mesenchymal transition-like features. Blood. 2012;119(24):5782-5794.
clasts. Blood. 2007;110(10):3744-3752.
20. Moreaux J, Hose D, Kassambara A, et al. Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell
migration. Blood. 2011;117(4):1280-1290. 21. Roussou M, Tasidou A, Dimopoulos MA, et al. Increased expression of macrophage inflammatory protein-1 on trephine biop- sies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia. 2009;23(11):2177-
2181.
22. Menu E, De Leenheer E, De Raeve H, et al.
Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis. 2006;23(5-6):291-300.
23.Dairaghi DJ, Oyajobi BO, Gupta A, et al. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood. 2012;120(7): 1449-1457.
24. Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, Mapara MY. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cas- cades mediating survival and proliferation in multiple myeloma (MM) cells. Blood. 2003;101(9):3568-3573.
25. Broxmeyer HE, Hangoc G, Cooper S, Campbell T, Ito S, Mantel C. AMD3100 and CD26 modulate mobilization, engraft- ment, and survival of hematopoietic stem and progenitor cells mediated by the SDF- 1/CXCL12-CXCR4 axis. Ann N Y Acad Sci. 2007;1106:1-19.
26. Bernardini G, Sciume G, Bosisio D, Morrone S, Sozzani S, Santoni A. CCL3 and CXCL12 regulate trafficking of mouse bone marrow NK cell subsets. Blood. 2008;111 (7):3626-3634.
27. Zannettino ACW, Farrugia AN, Kortesidis A, et al. Elevated serum levels of stromal- derived factor-1 are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res. 2005;65(5):1700-1709.
28. Shaughnessy JD, Jr., Qu P, Usmani S, et al. Pharmacogenomics of bortezomib test-
17.
Vandyke K, Zeissig MN, Hewett DR, et al. HIF-2a promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1. Cancer Res. 2017;77(20):5452-5463.
18.Uneda S, Hata H, Matsuno F, et al. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol. 2003;120(1):53-55.
19. Vallet S, Raje N, Ishitsuka K, et al. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interac- tion of multiple myeloma cells and osteo-
3186
haematologica | 2021; 106(12)